Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFS101A + Toripalimab in advanced solid tumors
NCT05165849Phase 2Withdrawn
- Sponsor
- GenFleet Therapeutics
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of GFS101A in solid tumor (advanced stage), sponsored by GenFleet Therapeutics. Planned start Apr 2022; status: withdrawn.
02
Drugs
GFS101A
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05165849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165849.